People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eyenovia, Inc. | — | Pharmaceuticals | Series C | $66.0M | $312.3M | 2020 |
| Tonix Pharmaceuticals Holding Corp. | — | Pharmaceuticals | Series A | $10.3M | $9.7M | 2012 |
Charles Mather at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Mather on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ernest Mario | 2 | 9 |
| Anthony Sun | 1 | 8 |
| Curt LaBelle | 1 | 7 |
| BARRY BUTLER | 1 | 6 |
| Tsontcho Ianchulev | 1 | 5 |
| FRED ESHELMAN | 1 | 5 |
| David Moss | 1 | 5 |
| Stuart Davidson | 1 | 3 |
| Gregory Sullivan | 1 | 3 |
| John Rhodes | 1 | 3 |
| Samuel Saks | 1 | 3 |
| Leland Gershell | 1 | 2 |
| John Gandolfo | 1 | 2 |
| Rachel Jacobson | 1 | 2 |
| Kenneth Lee | 1 | 2 |
| Fredric Eshelman | 1 | 2 |
| Patrick Grace | 1 | 2 |
| Benjamin Selzer | 1 | 2 |
| Michael Rowe | 1 | 2 |
| Donald Landry | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.